







an Open Access Journal by MDPI

Drug Repurposing and Reformulation for Cancer Treatment

Guest Editors:

Dr. Abhijit Date

R.K. Coit College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA

Dr. Arati Sharma

Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033. USA

Prof. Dr. Dhimant Desai

Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

Deadline for manuscript submissions:

closed (15 April 2024)

Message from the Guest Editors

Cancer is responsible for the second-highest number of deaths worldwide, our efforts to combat the problem have led to numerous discoveries, but several cancers still have poor prognoses. The traditional drug development path is time consuming. But drug repurposing can accentuate the clinical translation of the repurposed drug with a concomitant reduction in the development time and cost. Numerous clinical trials have been initiated to facilitate the translation of repurposed drugs for cancer therapy.

We are pleased to invite you to submit original contributions highlighting the potential of FDA-approved or previously discarded drugs in curbing cancer initiation, progression, and/or metastasis, and drug resistance. We also welcome contributions concerning the development of repurposed drug delivery systems to improve their bioavailability and/or targeting to augment therapeutic outcomes in cancers. We will consider contributions demonstrating in vitro and/or in vivo preclinical evidence of drug repurposing and/or reformulation for cancer therapy, and encourage contributions focusing on the exploration of repurposed drugs as an adjunct to standard chemo- and/or radiotherapy.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us